{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T21:03:46Z","timestamp":1778360626448,"version":"3.51.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Rift Valley fever virus (RVFV) is a zoonotic\u00a0arbovirus and pathogenic to both humans and animals. Currently, no proven effective RVFV drugs or licensed vaccine are available for human or animal use. Hence, there is an urgent need to develop effective treatment options to control this viral infection. RVFV glycoprotein N (GN), glycoprotein C (GC), and nucleocapsid (N) proteins are attractive antiviral drug targets due to their critical roles in RVFV replication. In present study, an integrated docking-based virtual screening of more than 6000 phytochemicals with known antiviral activities against these conserved RVFV proteins was conducted. The top five hit compounds, calyxin C, calyxin D, calyxin J, gericudranins A, and blepharocalyxin C displayed optimal binding against all three target proteins. Moreover, multiple parameters from the molecular dynamics (MD) simulations and MM\/GBSA analysis confirmed the stability of protein\u2013ligand complexes and revealed that these compounds may act as potential pan-inhibitors of RVFV replication. Our computational analyses may contribute toward the development of promising effective drugs against RVFV infection.<\/jats:p>","DOI":"10.1038\/s41598-022-13267-1","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T10:03:01Z","timestamp":1654250581000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Discovery of Rift Valley fever virus natural pan-inhibitors by targeting its multiple key proteins through computational approaches"],"prefix":"10.1038","volume":"12","author":[{"given":"Israr","family":"Fatima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sajjad","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mubarak A.","family":"Alamri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Usman","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Tahir ul Qamar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farah","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eid A.","family":"Alatawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faris F. Aba","family":"Alkhayl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wafa Abdullah","family":"Al-Megrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Almatroudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"key":"13267_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-ento-010715-023819","volume":"61","author":"KJ Linthicum","year":"2016","unstructured":"Linthicum, K. J., Britch, S. C. & Anyamba, A. Rift Valley fever: An emerging mosquito-borne disease. Annu. Rev. Entomol. 61, 395\u2013415 (2016).","journal-title":"Annu. Rev. Entomol."},{"key":"13267_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3390\/v3050493","volume":"3","author":"T Ikegami","year":"2011","unstructured":"Ikegami, T. & Makino, S. The pathogenesis of Rift Valley fever. Viruses 3, 493\u2013519 (2011).","journal-title":"Viruses"},{"key":"13267_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1128\/AAC.32.3.331","volume":"32","author":"RW Sidwell","year":"1988","unstructured":"Sidwell, R. W., Huffman, J. H., Barnett, B. B. & Pifat, D. Y. In vitro and in vivo Phlebovirus inhibition by ribavirin. Antimicrob. Agents Chemother. 32, 331\u2013336 (1988).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13267_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2183\/pjab.93.027","volume":"93","author":"Y Furuta","year":"2017","unstructured":"Furuta, Y., Komeno, T. & Nakamura, T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc. Jpn. Acad. Ser. B 93, 449\u2013463 (2017).","journal-title":"Proc. Jpn. Acad. Ser. B"},{"key":"13267_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.coviro.2018.08.011","volume":"33","author":"PJW Schreur","year":"2018","unstructured":"Schreur, P. J. W., Kormelink, R. & Kortekaas, J. Genome packaging of the Bunyavirales. Curr. Opin. Virol. 33, 151\u2013155 (2018).","journal-title":"Curr. Opin. Virol."},{"key":"13267_CR6","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1093\/nar\/19.19.5433","volume":"19","author":"R Muller","year":"1991","unstructured":"Muller, R., Argentini, C., Bouloy, M., Prehaud, C. & Bishop, D. Completion of the genome sequence of Rift Valley fever phlebovirus indicates that the L RNA is negative sense and codes for a putative transcriptase-replicase [corrected]. Nucleic Acids Res. 19, 5433 (1991).","journal-title":"Nucleic Acids Res."},{"key":"13267_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","volume":"170","author":"CS Schmaljohn","year":"1989","unstructured":"Schmaljohn, C. S. et al. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170, 184\u2013192 (1989).","journal-title":"Virology"},{"key":"13267_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1073\/pnas.1013155108","volume":"108","author":"K Terasaki","year":"2011","unstructured":"Terasaki, K., Murakami, S., Lokugamage, K. G. & Makino, S. Mechanism of tripartite RNA genome packaging in Rift Valley fever virus. Proc. Natl. Acad. Sci. 108, 804\u2013809 (2011).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"13267_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-5-82","volume":"5","author":"L Liu","year":"2008","unstructured":"Liu, L., Celma, C. C. & Roy, P. Rift Valley fever virus structural proteins: Expression, characterization and assembly of recombinant proteins. Virol. J. 5, 1\u201313 (2008).","journal-title":"Virol. J."},{"key":"13267_CR10","doi-asserted-by":"publisher","first-page":"3762","DOI":"10.1128\/JVI.02483-08","volume":"83","author":"JT Huiskonen","year":"2009","unstructured":"Huiskonen, J. T., Overby, A. K., Weber, F. & Gr\u00fcnewald, K. Electron cryo-microscopy and single-particle averaging of Rift Valley fever virus: evidence for GN-GC glycoprotein heterodimers. J. Virol. 83, 3762\u20133769 (2009).","journal-title":"J. Virol."},{"key":"13267_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003922","volume":"10","author":"B Brennan","year":"2014","unstructured":"Brennan, B., Welch, S. R. & Elliott, R. M. The consequences of reconfiguring the ambisense S genome segment of Rift Valley fever virus on viral replication in mammalian and mosquito cells and for genome packaging. PLoS Pathog. 10, e1003922 (2014).","journal-title":"PLoS Pathog."},{"key":"13267_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002030","volume":"7","author":"F Ferron","year":"2011","unstructured":"Ferron, F. et al. The hexamer structure of the Rift Valley fever virus nucleoprotein suggests a mechanism for its assembly into ribonucleoprotein complexes. PLoS Pathog. 7, e1002030 (2011).","journal-title":"PLoS Pathog."},{"key":"13267_CR13","doi-asserted-by":"publisher","first-page":"11769","DOI":"10.1073\/pnas.1001760107","volume":"107","author":"DD Raymond","year":"2010","unstructured":"Raymond, D. D., Piper, M. E., Gerrard, S. R. & Smith, J. L. Structure of the Rift Valley fever virus nucleocapsid protein reveals another architecture for RNA encapsidation. Proc. Natl. Acad. Sci. 107, 11769\u201311774 (2010).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"13267_CR14","first-page":"320","volume":"10","author":"MU Mirza","year":"2020","unstructured":"Mirza, M. U. & Froeyen, M. Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. J. Pharmaceut. Anal. 10, 320\u2013328 (2020).","journal-title":"J. Pharmaceut. Anal."},{"key":"13267_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/CAD.0000000000000727","volume":"30","author":"I Muneer","year":"2019","unstructured":"Muneer, I., Tusleem, K., Abdul Rauf, S., Hussain, H. M. & Siddiqi, A. R. Discovery of selective inhibitors for cyclic AMP response element-binding protein: A combined ligand and structure-based resources pipeline. Anticancer Drugs 30, 363\u2013373 (2019).","journal-title":"Anticancer Drugs"},{"key":"13267_CR16","doi-asserted-by":"publisher","first-page":"104371","DOI":"10.1016\/j.meegid.2020.104371","volume":"84","author":"H Khalid","year":"2020","unstructured":"Khalid, H. et al. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase. Infect. Genet. Evol. 84, 104371 (2020).","journal-title":"Infect. Genet. Evol."},{"key":"13267_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jmgm.2018.07.010","volume":"85","author":"S Durdagi","year":"2018","unstructured":"Durdagi, S. et al. Investigating the molecular mechanism of staphylococcal DNA gyrase inhibitors: A combined ligand-based and structure-based resources pipeline. J. Mol. Graph. Model. 85, 122\u2013129. https:\/\/doi.org\/10.1016\/j.jmgm.2018.07.010 (2018).","journal-title":"J. Mol. Graph. Model."},{"key":"13267_CR18","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1002\/jmv.25357","volume":"91","author":"MU Mirza","year":"2019","unstructured":"Mirza, M. U. et al. Perspectives towards antiviral drug discovery against Ebola virus. J. Med. Virol. 91, 2029\u20132048 (2019).","journal-title":"J. Med. Virol."},{"key":"13267_CR19","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.saa.2014.10.045","volume":"136","author":"NA Saleh","year":"2015","unstructured":"Saleh, N. A. The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors. Spectrochim. Acta Part A Mol. Biomol. Spectrosc. 136, 1523\u20131529 (2015).","journal-title":"Spectrochim. Acta Part A Mol. Biomol. Spectrosc."},{"key":"13267_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/cbdd.13914","volume":"98","author":"S Ahmad","year":"2021","unstructured":"Ahmad, S. et al. Fragment\u2010based in silico design of SARS CoV\u20102 main protease inhibitors. Chem. Biol. Drug Des. 98, 604\u2013619 (2021).","journal-title":"Chem. Biol. Drug Des."},{"key":"13267_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3390\/biom9040133","volume":"9","author":"FG Durrani","year":"2019","unstructured":"Durrani, F. G. et al. Mutagenesis of DsbAss is crucial for the signal recognition particle mechanism in Escherichia coli: Insights from molecular dynamics simulations. Biomolecules 9, 133 (2019).","journal-title":"Biomolecules"},{"key":"13267_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/biom9040124","volume":"9","author":"N Ikram","year":"2019","unstructured":"Ikram, N. et al. Inhibition of oncogenic kinases: An in vitro validated computational approach identified potential multi-target anticancer compounds. Biomolecules 9, 124 (2019).","journal-title":"Biomolecules"},{"key":"13267_CR23","doi-asserted-by":"publisher","first-page":"104371","DOI":"10.1016\/j.meegid.2020.104371","volume":"84","author":"H Khalid","year":"2020","unstructured":"Khalid, H. et al. Discovery of novel hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase. Infect. Genet. Evolut. 84, 104371 (2020).","journal-title":"Infect. Genet. Evolut."},{"key":"13267_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-43129-2","volume":"9","author":"MU Mirza","year":"2019","unstructured":"Mirza, M. U. et al. In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo hemorrhagic fever virus inhibitors. Sci. Rep. 9, 1\u201318 (2019).","journal-title":"Sci. Rep."},{"key":"13267_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.drudis.2012.06.002","volume":"17","author":"J Du","year":"2012","unstructured":"Du, J., Cross, T. A. & Zhou, H.-X. Recent progress in structure-based anti-influenza drug design. Drug Discov. Today 17, 1111\u20131120 (2012).","journal-title":"Drug Discov. Today"},{"key":"13267_CR26","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1517\/17460441.2012.714364","volume":"7","author":"AC Shurtleff","year":"2012","unstructured":"Shurtleff, A. C., Nguyen, T. L., Kingery, D. A. & Bavari, S. Therapeutics for filovirus infection: Traditional approaches and progress towards in silico drug design. Expert Opin. Drug Discov. 7, 935\u2013954 (2012).","journal-title":"Expert Opin. Drug Discov."},{"key":"13267_CR27","doi-asserted-by":"crossref","unstructured":"Nitsche, C. Strategies towards protease inhibitors for emerging flaviviruses. in Dengue and Zika: Control and Antiviral Treatment Strategies. 175\u2013186. (2018).","DOI":"10.1007\/978-981-10-8727-1_13"},{"key":"13267_CR28","doi-asserted-by":"crossref","unstructured":"Rehman, A., Ashfaq, U. A., Shahid, F., Noor, F. & Aslam, S. The screening of phytochemicals against NS5 polymerase to treat Zika virus infection: Integrated computational based approach. in Combinatorial Chemistry & High Throughput Screening. (2021).","DOI":"10.2174\/1386207324666210712091920"},{"key":"13267_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105537","volume":"155","author":"MU Mirza","year":"2020","unstructured":"Mirza, M. U. et al. Discovery of HIV entry inhibitors via a hybrid CXCR4 and CCR5 receptor pharmacophore-based virtual screening approach. Eur. J. Pharm. Sci. 155, 105537 (2020).","journal-title":"Eur. J. Pharm. Sci."},{"key":"13267_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3923\/ijp.2016.621.632","volume":"12","author":"MT ul Qamar","year":"2016","unstructured":"ul Qamar, M. T. et al. Discovery of novel dengue NS2B\/NS3 protease inhibitors using pharmacophore modeling and molecular docking based virtual screening of the zinc database. Int. J. Pharmacol. 12, 621\u2013632 (2016).","journal-title":"Int. J. Pharmacol."},{"key":"13267_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3329\/bjp.v9i3.18555","volume":"9","author":"MT ul Qamar","year":"2014","unstructured":"ul Qamar, M. T., Mumtaz, A., Ashfaq, U. A., Adeel, M. M. & Fatima, T. Potential of plant alkaloids as dengue ns3 protease inhibitors: Molecular docking and simulation approach. Bangladesh J. Pharmacol. 9, 262\u2013267 (2014).","journal-title":"Bangladesh J. Pharmacol."},{"key":"13267_CR32","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/nsb0902-646","volume":"9","author":"M Karplus","year":"2002","unstructured":"Karplus, M. & McCammon, J. A. Molecular dynamics simulations of biomolecules. Nat. Struct. Biol. 9, 646\u2013652 (2002).","journal-title":"Nat. Struct. Biol."},{"key":"13267_CR33","doi-asserted-by":"publisher","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","volume":"119","author":"E Wang","year":"2019","unstructured":"Wang, E. et al. End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: Strategies and applications in drug design. Chem. Rev. 119, 9478\u20139508 (2019).","journal-title":"Chem. Rev."},{"key":"13267_CR34","first-page":"920","volume":"1","author":"U Norinder","year":"2006","unstructured":"Norinder, U. & Bergstr\u00f6m, C. A. Prediction of ADMET properties. ChemMedChem Chem. Enabling Drug Discov. 1, 920\u2013937 (2006).","journal-title":"ChemMedChem Chem. Enabling Drug Discov."},{"key":"13267_CR35","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1107\/S0907444998009378","volume":"54","author":"JL Sussman","year":"1998","unstructured":"Sussman, J. L. et al. Protein data bank (PDB): Database of three-dimensional structural information of biological macromolecules. Acta Crystallogr. Sect. D. Biol. Crystallogr. 54, 1078\u20131084 (1998).","journal-title":"Acta Crystallogr. Sect. D. Biol. Crystallogr."},{"key":"13267_CR36","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2174\/156802608786786624","volume":"8","author":"S Vilar","year":"2008","unstructured":"Vilar, S., Cozza, G. & Moro, S. Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery. Curr. Top. Med. Chem. 8, 1555\u20131572 (2008).","journal-title":"Curr. Top. Med. Chem."},{"key":"13267_CR37","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"S Kim","year":"2016","unstructured":"Kim, S. et al. PubChem substance and compound databases. Nucleic Acids Res. 44, D1202\u2013D1213 (2016).","journal-title":"Nucleic Acids Res."},{"key":"13267_CR38","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/14786419.2016.1233409","volume":"31","author":"A Mumtaz","year":"2017","unstructured":"Mumtaz, A. et al. MPD3: A useful medicinal plants database for drug designing. Nat. Prod. Res. 31, 1228\u20131236 (2017).","journal-title":"Nat. Prod. Res."},{"key":"13267_CR39","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1021\/ci049714+","volume":"45","author":"JJ Irwin","year":"2005","unstructured":"Irwin, J. J. & Shoichet, B. K. ZINC\u2014A free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45, 177\u2013182 (2005).","journal-title":"J. Chem. Inf. Model."},{"key":"13267_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006155","volume":"11","author":"TJ Mottram","year":"2017","unstructured":"Mottram, T. J. et al. Mutational analysis of Rift Valley fever phlebovirus nucleocapsid protein indicates novel conserved, functional amino acids. PLoS Negl. Trop. Dis. 11, e0006155 (2017).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"13267_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005813","volume":"12","author":"P Guardado-Calvo","year":"2016","unstructured":"Guardado-Calvo, P. et al. Mechanistic insight into bunyavirus-induced membrane fusion from structure-function analyses of the hantavirus envelope glycoprotein Gc. PLoS Pathol. 12, e1005813 (2016).","journal-title":"PLoS Pathol."},{"key":"13267_CR42","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41564-019-0411-z","volume":"4","author":"Q Wang","year":"2019","unstructured":"Wang, Q. et al. Neutralization mechanism of human monoclonal antibodies against Rift Valley fever virus. Nat. Microbiol. 4, 1231\u20131241 (2019).","journal-title":"Nat. Microbiol."},{"key":"13267_CR43","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1021\/jm900776m","volume":"53","author":"M Podvinec","year":"2010","unstructured":"Podvinec, M. et al. Novel inhibitors of dengue virus methyltransferase: Discovery by in vitro-driven virtual screening on a desktop computer grid. J. Med. Chem. 53, 1483\u20131495 (2010).","journal-title":"J. Med. Chem."},{"key":"13267_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.13432","volume":"44","author":"I Khalifa","year":"2020","unstructured":"Khalifa, I., Zhu, W., Mohammed, H. H. H., Dutta, K. & Li, C. Tannins inhibit SARS-CoV-2 through binding with catalytic dyad residues of 3CLpro: An in silico approach with 19 structural different hydrolysable tannins. J. Food Biochem. 44, e13432 (2020).","journal-title":"J. Food Biochem."},{"key":"13267_CR45","unstructured":"DeLano, W. L. The PyMOL Molecular Graphics System. (Delano Scientific, San Carlos, 2002)."},{"key":"13267_CR46","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1017\/S0033583515000190","volume":"48","author":"Y Wang","year":"2015","unstructured":"Wang, Y. et al. In silico ADME\/T modelling for rational drug design. Q. Rev. Biophys. 48, 488\u2013515 (2015).","journal-title":"Q. Rev. Biophys."},{"key":"13267_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3\u201325 (1997).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"13267_CR48","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s00044-011-9723-0","volume":"21","author":"A Jarrahpour","year":"2012","unstructured":"Jarrahpour, A. et al. Petra, Osiris and Molinspiration (POM) together as a successful support in drug design: antibacterial activity and biopharmaceutical characterization of some azo Schiff bases. Med. Chem. Res. 21, 1984\u20131990 (2012).","journal-title":"Med. Chem. Res."},{"key":"13267_CR49","doi-asserted-by":"publisher","first-page":"W257","DOI":"10.1093\/nar\/gky318","volume":"46","author":"P Banerjee","year":"2018","unstructured":"Banerjee, P., Eckert, A. O., Schrey, A. K. & Preissner, R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 46, W257\u2013W263 (2018).","journal-title":"Nucleic Acids Res."},{"key":"13267_CR50","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/jcc.540020311","volume":"2","author":"PK Weiner","year":"1981","unstructured":"Weiner, P. K. & Kollman, P. A. AMBER: Assisted model building with energy refinement. A general program for modeling molecules and their interactions. J. Comput. Chem. 2, 287\u2013303 (1981).","journal-title":"J. Comput. Chem."},{"key":"13267_CR51","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/wcms.1121","volume":"3","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer, R., Case, D. A. & Walker, R. C. An overview of the Amber biomolecular simulation package. Wiley Interdiscip. Rev. Comput. Mol. Sci. 3, 198\u2013210 (2013).","journal-title":"Wiley Interdiscip. Rev. Comput. Mol. Sci."},{"key":"13267_CR52","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V","volume":"22","author":"V Kr\u00e4utler","year":"2001","unstructured":"Kr\u00e4utler, V., Van Gunsteren, W. F. & H\u00fcnenberger, P. H. A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations. J. Comput. Chem. 22, 501\u2013508 (2001).","journal-title":"J. Comput. Chem."},{"key":"13267_CR53","doi-asserted-by":"publisher","DOI":"10.1103\/PhysRevE.75.056707","volume":"75","author":"G Bussi","year":"2007","unstructured":"Bussi, G. & Parrinello, M. Accurate sampling using Langevin dynamics. Phys. Rev. E 75, 056707 (2007).","journal-title":"Phys. Rev. E"},{"key":"13267_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104451","volume":"84","author":"D Bhowmik","year":"2020","unstructured":"Bhowmik, D. et al. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. Infect. Genet. Evol. 84, 104451 (2020).","journal-title":"Infect. Genet. Evol."},{"key":"13267_CR55","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe, D. R. & Cheatham, T. E. III. PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J. Chem. Theory Comput. 9, 3084\u20133095 (2013).","journal-title":"J. Chem. Theory Comput."},{"key":"13267_CR56","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.9965","volume":"8","author":"VL Kouznetsova","year":"2020","unstructured":"Kouznetsova, V. L., Zhang, A., Tatineni, M., Miller, M. A. & Tsigelny, I. F. Potential COVID-19 papain-like protease PLpro inhibitors: Repurposing FDA-approved drugs. PeerJ 8, e9965 (2020).","journal-title":"PeerJ"},{"key":"13267_CR57","doi-asserted-by":"publisher","DOI":"10.4324\/9780203967324","volume-title":"BIOS Instant Notes in Molecular Biology","author":"P Turner","year":"2007","unstructured":"Turner, P., McLennan, A., Bates, A. & White, M. BIOS Instant Notes in Molecular Biology (Garland Science, 2007)."},{"key":"13267_CR58","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.bpj.2009.11.011","volume":"98","author":"A Kuzmanic","year":"2010","unstructured":"Kuzmanic, A. & Zagrovic, B. Determination of ensemble-average pairwise root mean-square deviation from experimental B-factors. Biophys. J . 98, 861\u2013871 (2010).","journal-title":"Biophys. J ."},{"key":"13267_CR59","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/minf.201100135","volume":"31","author":"N Homeyer","year":"2012","unstructured":"Homeyer, N. & Gohlke, H. Free energy calculations by the molecular mechanics Poisson\u2212Boltzmann surface area method. Mol. Inf. 31, 114\u2013122 (2012).","journal-title":"Mol. Inf."},{"key":"13267_CR60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov. 10, 449\u2013461 (2015).","journal-title":"Expert Opin. Drug Discov."},{"key":"13267_CR61","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1021\/ci300385h","volume":"52","author":"HK Srivastava","year":"2012","unstructured":"Srivastava, H. K. & Sastry, G. N. Molecular dynamics investigation on a series of HIV protease inhibitors: Assessing the performance of MM-PBSA and MM-GBSA approaches. J. Chem. Inf. Model. 52, 3088\u20133098 (2012).","journal-title":"J. Chem. Inf. Model."},{"key":"13267_CR62","doi-asserted-by":"publisher","first-page":"14450","DOI":"10.1039\/C7CP07623A","volume":"20","author":"H Sun","year":"2018","unstructured":"Sun, H. et al. Assessing the performance of MM\/PBSA and MM\/GBSA methods. 7. Entropy effects on the performance of end-point binding free energy calculation approaches. PCCP 20, 14450\u201314460 (2018).","journal-title":"PCCP"},{"key":"13267_CR63","doi-asserted-by":"publisher","first-page":"16719","DOI":"10.1039\/C4CP01388C","volume":"16","author":"H Sun","year":"2014","unstructured":"Sun, H., Li, Y., Tian, S., Xu, L. & Hou, T. Assessing the performance of MM\/PBSA and MM\/GBSA methods. 4. Accuracies of MM\/PBSA and MM\/GBSA methodologies evaluated by various simulation protocols using PDBbind data set. PCCP 16, 16719\u201316729 (2014).","journal-title":"PCCP"},{"key":"13267_CR64","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S0959-440X(96)80061-3","volume":"6","author":"T Lengauer","year":"1996","unstructured":"Lengauer, T. & Rarey, M. Computational methods for biomolecular docking. Curr. Opin. Struct. Biol. 6, 402\u2013406 (1996).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"13267_CR65","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1128\/AAC.01299-07","volume":"52","author":"H Nakata","year":"2008","unstructured":"Nakata, H. et al. Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugs. Antimicrob. Agents Chemother. 52, 2111\u20132119 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13267_CR66","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3851\/IMP3044","volume":"21","author":"B Lin","year":"2016","unstructured":"Lin, B., He, S., Yim, H. J., Liang, T. J. & Hu, Z. Evaluation of antiviral drug synergy in an infectious HCV system. Antivir. Ther. 21, 595 (2016).","journal-title":"Antivir. Ther."},{"key":"13267_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2377-9-S1-S1","volume":"9","author":"K Tsaioun","year":"2009","unstructured":"Tsaioun, K., Bottlaender, M. & Mabondzo, A. ADDME\u2013Avoiding drug development mistakes early: Central nervous system drug discovery perspective. BMC Neurol. 9, 1\u201311 (2009).","journal-title":"BMC Neurol."},{"key":"13267_CR68","volume":"3","author":"LZ Benet","year":"1996","unstructured":"Benet, L. Z., Kroetz, D., Sheiner, L., Hardman, J. & Limbird, L. Pharmacokinetics: the dynamics of drug absorption, distribution, metabolism, and elimination. Goodman Gilman\u2019s Pharmacol. Basis Ther. 3, e27 (1996).","journal-title":"Goodman Gilman\u2019s Pharmacol. Basis Ther."},{"key":"13267_CR69","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.mpaic.2017.04.007","volume":"18","author":"S Chillistone","year":"2017","unstructured":"Chillistone, S. & Hardman, J. G. Factors affecting drug absorption and distribution. Anaesth. Intensive Care Med. 18, 335\u2013339 (2017).","journal-title":"Anaesth. Intensive Care Med."},{"key":"13267_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1146\/annurev.pa.01.040161.000333","volume":"1","author":"LS Schanker","year":"1961","unstructured":"Schanker, L. S. Mechanisms of drug absorption and distribution. Annu. Rev. Pharmacol. 1, 29\u201345 (1961).","journal-title":"Annu. Rev. Pharmacol."},{"key":"13267_CR71","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2165\/00003088-200342020-00004","volume":"42","author":"MT Donato","year":"2003","unstructured":"Donato, M. T. & Castell, J. V. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism. Clin. Pharmacokinet. 42, 153\u2013178 (2003).","journal-title":"Clin. Pharmacokinet."},{"key":"13267_CR72","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger, U. M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103\u2013141 (2013).","journal-title":"Pharmacol. Ther."},{"key":"13267_CR73","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.toxlet.2004.12.008","volume":"156","author":"D Balayssac","year":"2005","unstructured":"Balayssac, D., Authier, N., Cayre, A. & Coudore, F. Does inhibition of P-glycoprotein lead to drug\u2013drug interactions?. Toxicol. Lett. 156, 319\u2013329 (2005).","journal-title":"Toxicol. Lett."},{"key":"13267_CR74","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1590\/S1984-82502012000300002","volume":"48","author":"KMR Srivalli","year":"2012","unstructured":"Srivalli, K. M. R. & Lakshmi, P. K. Overview of P-glycoprotein inhibitors: A rational outlook. Braz. J. Pharm. Sci. 48, 353\u2013367 (2012).","journal-title":"Braz. J. Pharm. Sci."},{"key":"13267_CR75","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","volume":"48","author":"MVS Varma","year":"2003","unstructured":"Varma, M. V. S., Ashokraj, Y., Dey, C. S. & Panchagnula, R. P-glycoprotein inhibitors and their screening: A perspective from bioavailability enhancement. Pharmacol. Res. 48, 347\u2013359 (2003).","journal-title":"Pharmacol. Res."},{"key":"13267_CR76","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1021\/acs.jcim.0c00057","volume":"60","author":"H Guterres","year":"2020","unstructured":"Guterres, H. & Im, W. Improving protein-ligand docking results with high-throughput molecular dynamics simulations. J. Chem. Inf. Model. 60, 2189\u20132198 (2020).","journal-title":"J. Chem. Inf. Model."},{"key":"13267_CR77","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2142\/biophysico.13.0_181","volume":"13","author":"T Sakano","year":"2016","unstructured":"Sakano, T., Mahamood, M. I., Yamashita, T. & Fujitani, H. Molecular dynamics analysis to evaluate docking pose prediction. Biophys. Physicobiol. 13, 181\u2013194 (2016).","journal-title":"Biophys. Physicobiol."},{"key":"13267_CR78","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1021\/acs.jcim.7b00588","volume":"58","author":"S Makeneni","year":"2018","unstructured":"Makeneni, S., Thieker, D. F. & Woods, R. J. Applying pose clustering and MD simulations to eliminate false positives in molecular docking. J. Chem. Inf. Model. 58, 605\u2013614 (2018).","journal-title":"J. Chem. Inf. Model."},{"key":"13267_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2020.107378","volume":"89","author":"F Anwar","year":"2020","unstructured":"Anwar, F. et al. New naphthalene derivative for cost-effective AChE inhibitors for Alzheimer\u2019s treatment: In silico identification, in vitro and in vivo validation. Comput. Biol. Chem. 89, 107378 (2020).","journal-title":"Comput. Biol. Chem."},{"key":"13267_CR80","first-page":"54","volume":"17","author":"K Iman","year":"2018","unstructured":"Iman, K. et al. In silico structure-based identification of novel acetylcholinesterase inhibitors against Alzheimer\u2019s disease. CNS Neurol. Disord. Drug Targets (Formerly Curr. Drug Targets-CNS Neurol. Disord.) 17, 54\u201368 (2018).","journal-title":"CNS Neurol. Disord. Drug Targets (Formerly Curr. Drug Targets-CNS Neurol. Disord.)"},{"key":"13267_CR81","doi-asserted-by":"publisher","first-page":"7130","DOI":"10.1093\/nar\/gkz551","volume":"47","author":"M Vanmeert","year":"2019","unstructured":"Vanmeert, M. et al. Rational design of an XNA ligase through docking of unbound nucleic acids to toroidal proteins. Nucleic Acids Res. 47, 7130\u20137142 (2019).","journal-title":"Nucleic Acids Res."},{"key":"13267_CR82","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/pr9010071","volume":"9","author":"OMH Salo-Ahen","year":"2021","unstructured":"Salo-Ahen, O. M. H. et al. Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes 9, 71 (2021).","journal-title":"Processes"},{"key":"13267_CR83","volume-title":"Computer-Aided Drug Design 133\u2013161","author":"R Shukla","year":"2020","unstructured":"Shukla, R. & Tripathi, T. Computer-Aided Drug Design 133\u2013161 (Springer, 2020)."},{"key":"13267_CR84","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s41745-019-00141-9","volume":"100","author":"G Bulusu","year":"2020","unstructured":"Bulusu, G. & Desiraju, G. R. Strong and weak hydrogen bonds in protein\u2013ligand recognition. J. Indian Inst. Sci. 100, 31\u201341 (2020).","journal-title":"J. Indian Inst. Sci."},{"key":"13267_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112771","volume":"208","author":"DL Cramer","year":"2020","unstructured":"Cramer, D. L. et al. Some thermodynamic effects of varying nonpolar surfaces in protein-ligand interactions. Eur. J. Med. Chem. 208, 112771 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"13267_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-20362-9","volume":"8","author":"MK Islam","year":"2018","unstructured":"Islam, M. K. et al. Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound. Sci. Rep. 8, 1\u201312 (2018).","journal-title":"Sci. Rep."},{"key":"13267_CR87","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","volume":"104","author":"D Scharton","year":"2014","unstructured":"Scharton, D. et al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antiviral Res. 104, 84\u201392 (2014).","journal-title":"Antiviral Res."},{"key":"13267_CR88","doi-asserted-by":"publisher","first-page":"e00669","DOI":"10.1128\/AAC.00669-19","volume":"63","author":"B Borrego","year":"2019","unstructured":"Borrego, B., de \u00c1vila, A. I., Domingo, E. & Brun, A. Lethal mutagenesis of Rift Valley fever virus induced by favipiravir. Antimicrob. Agents Chemother. 63, e00669-e1619 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"13267_CR89","doi-asserted-by":"publisher","first-page":"651","DOI":"10.2217\/fvl-2017-0060","volume":"12","author":"C Atkins","year":"2017","unstructured":"Atkins, C. & Freiberg, A. N. Recent advances in the development of antiviral therapeutics for Rift Valley fever virus infection. Futur. Virol. 12, 651\u2013665 (2017).","journal-title":"Futur. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13267-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13267-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13267-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T03:48:34Z","timestamp":1669348114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-13267-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["13267"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-13267-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,3]]},"assertion":[{"value":"27 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9260"}}